Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Equillium Inc (EQ)

Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,615
  • Shares Outstanding, K 63,227
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,400 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.22

Options Overview Details

View History
  • Implied Volatility 118.77% (-179.80%)
  • Historical Volatility 108.10%
  • IV Percentile 2%
  • IV Rank 3.19%
  • IV High 1,340.64% on 11/19/25
  • IV Low 78.53% on 12/18/25
  • Expected Move (DTE 25) 0.64 (31.72%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 78
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 704
  • Open Int (30-Day) 4,230
  • Expected Range 1.37 to 2.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 4
  • High Estimate $-0.04
  • Low Estimate $-0.05
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) +83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +25.62%
on 03/30/26
2.17 -7.37%
on 04/15/26
-0.12 (-5.63%)
since 03/20/26
3-Month
1.10 +82.73%
on 01/21/26
2.70 -25.56%
on 03/16/26
+0.86 (+74.78%)
since 01/20/26
52-Week
0.27 +644.44%
on 06/24/25
2.70 -25.56%
on 03/16/26
+1.54 (+325.40%)
since 04/17/25

Most Recent Stories

More News
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.01 (-1.95%)
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.01 (-1.95%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.01 (-1.95%)
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing,...

EQ : 2.01 (-1.95%)
Equillium to Participate in the 38th Annual Roth Conference

LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.01 (-1.95%)
Equillium Announces $35 Million Financing with RA Capital Management

Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA...

EQ : 2.01 (-1.95%)
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.01 (-1.95%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.01 (-1.95%)
Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...

EQ : 2.01 (-1.95%)
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor...

EQ : 2.01 (-1.95%)

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.20
1st Resistance Point 2.11
Last Price 2.01
1st Support Level 1.87
2nd Support Level 1.72
3rd Support Level 1.63

See More

52-Week High 2.70
Last Price 2.01
Fibonacci 61.8% 1.77
Fibonacci 50% 1.49
Fibonacci 38.2% 1.20
52-Week Low 0.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.